Key clinical point: Treatment of male breast cancer has evolved, with differences noted in surgery, radiotherapy, and systemic therapy noted over a decade.

Major finding: This analysis shows increased use of total mastectomy, radiotherapy after breast-conserving surgery, endocrine therapy, and genomic testing, though 5-year overall survival remained similar over time.

Study details: Retrospective analysis including 10,873 male patients with breast cancer diagnosed between 2004 and 2014.

Disclosures: The study by Dr. Yadav and colleagues was partly supported by the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Breast Cancer awarded to the Mayo Clinic. Dr. Yadav reported no conflicts of interest. Coauthors reported disclosures related to Menarini Silicon Biosystems, Genentech, Immunomedics, Pfizer, and Merck.